Alkermes Settles With Amneal Over Vivitrol Patent Dispute

Alkermes has entered into a settlement and license agreementT with Amneal Pharmaceuticals to resolve Amneal’s inter partes review petition challenging U.S. Patent Number 7,919,499 for Vivitrol (naltrexone for extended-release injectable suspension), expiring in 2029.

• Parties agreed to request termination of IPR & Alkermes gets Amneal non-exclusive right to market a generic formulation of Vivitrol in U.S. beginning sometime in 2028 or earlier under some circumstances
• Other terms of pact confidential
• Oral hearing with PTAB of U.S. Patent & Trademark Office scheduled on July 29 cancelled
• ALKS up more than 4%
• NOTE: Nov. 7, Amneal Swipe at Alkermes’ Opioid Overdose Rx ...